Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Orforglipron and Tirzepatide — mechanism, side effects, legal status, and pricing.
Orforglipron (brand name Foundayo) is Eli Lilly's oral non-peptide small-molecule GLP-1 receptor agonist. Unlike oral semaglutide (Rybelsus), it does not require the SNAC absorption enhancer or fasting/water restrictions — it can be taken any time of day. Not a peptide.
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It has a half-life of approximately 5 days, allowing once-weekly subcutaneous dosing.
Orforglipron
Tirzepatide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Orforglipron
No pricing data yet.
Check Orforglipron prices →Tirzepatide
COA corpus from Disclosed Labs — independently tested batches only.
Orforglipron
2
COAs
99.3%
Avg purity
2
Labs
Tirzepatide
306
COAs
99.7%
Avg purity
15
Labs
ATTAIN-1 Phase 3 (n=3,127, non-diabetic obesity): mean body-weight change -11.2% with 36 mg at week 72 vs -2.1% placebo; ~59.6% of the 36 mg arm achieved ≥10% loss (Wharton et al., NEJM 2025). ATTAIN-2 (T2D obesity) and the ACHIEVE program (T2D glycemic control) were also positive. FDA approved April 1, 2026 as Foundayo under the Commissioner's National Priority Voucher program for adults with obesity or overweight with ≥1 weight-related comorbidity — the first oral small-molecule GLP-1 RA approved in the US.
Key references
The SURPASS program established efficacy in type 2 diabetes, including SURPASS-2 (Frias et al., NEJM 2021), in which tirzepatide was superior to semaglutide 1 mg for A1C reduction and body weight. The SURMOUNT-1 obesity trial (Jastreboff et al., NEJM 2022) demonstrated up to approximately 20.9% mean body-weight reduction at 15 mg over 72 weeks. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed large reductions in apnea-hypopnea index in obstructive sleep apnea with obesity, supporting the 2024 FDA indication (Zepbound for moderate-to-severe OSA in adults with obesity). The SUMMIT trial (Packer et al., NEJM 2025) demonstrated a lower risk of cardiovascular death or worsening heart failure in HFpEF with obesity.
Key references
Orforglipron and Tirzepatide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs